Pacific Biosciences Of California (PACB) EBITDA Margin (2010 - 2026)
Pacific Biosciences Of California (PACB) posted EBITDA Margin of 108.41% for Q2 2026, down 554.64% on a QoQ basis from 16.56% in Q1 2026, and down 231.0% year-over-year from 82.76% in Q2 2025.
Powered by 
Analysis
Pacific Biosciences Of California (PACB) EBITDA Margin (2010 - 2026) Analysis & Trends
Pacific Biosciences Of California has reported EBITDA Margin for 17 years, with the latest figure at 108.41% in Q2 2026.
- On a quarterly basis, EBITDA Margin fell 231.0% year-over-year to 108.41% in Q2 2026; TTM through Jun 2026 was 77.42%, a 35563.0% increase from a year earlier, with the FY2025 full-year figure at 338.03%, down 3902.0% from the prior year.
- EBITDA Margin was 108.41% for Q2 2026 at Pacific Biosciences Of California, down from 16.56% in the prior quarter.
- The five-year high for EBITDA Margin was 16.56% in Q1 2026, with the low at 1140.7% in Q1 2025.
- Average EBITDA Margin over 5 years is 242.94%, with a median of 167.46% recorded in 2022.
- The sharpest annual moves came in 2025 and 2026: EBITDA Margin sank 93940 bps in 2025, then surged 112414 bps in 2026.
- Over 5 years, EBITDA Margin stood at 309.0% in 2022, then soared by 53 bps to 144.86% in 2023, then plunged by 164 bps to 382.83% in 2024, then surged by 78 bps to 86.12% in 2025, then slipped by 26 bps to 108.41% in 2026.
- The last three EBITDA Margin figures came in at 108.41% (Q2 2026), 16.56% (Q1 2026), and 86.12% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 225.48 Bn | 221.41 Bn | 8.34 Bn | 17.40% |
| 2 | Danaher | 144.42 Bn | 140.08 Bn | 3.61 Bn | 17.99% |
| 3 | Agilent Technologies | 40.86 Bn | 39.11 Bn | 1.04 Bn | 23.64% |
| 4 | Illumina | 30.97 Bn | 29.80 Bn | 770.00 Mn | 21.14% |
| 5 | Revvity | 13.85 Bn | 12.83 Bn | 416.87 Mn | 12.24% |
| 6 | Bio-Techne | 11.27 Bn | 11.01 Bn | 211.39 Mn | 23.13% |
| 7 | Bio-Rad Laboratories | 10.11 Bn | 8.49 Bn | 345.80 Mn | 11.15% |
| 8 | Repligen | 9.33 Bn | 8.31 Bn | 110.04 Mn | 6.85% |
| 9 | 10x Genomics | 8.77 Bn | 8.21 Bn | 112.50 Mn | -12.95% |
| 10 | Pacific Biosciences Of California | 400.74 Mn | 163.87 Mn | 12.64 Mn | -108.41% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -108.41% |
| Mar 31, 2026 | -16.56% |
| Dec 31, 2025 | -86.12% |
| Sep 30, 2025 | -94.73% |
| Jun 30, 2025 | -106.11% |
| Mar 31, 2025 | -1,140.70% |
| Dec 31, 2024 | -382.83% |
| Sep 30, 2024 | -149.83% |
| Jun 30, 2024 | -478.57% |
| Mar 31, 2024 | -201.29% |
| Dec 31, 2023 | -144.86% |
| Sep 30, 2023 | -142.91% |
| Jun 30, 2023 | -147.87% |
| Mar 31, 2023 | -227.50% |
| Dec 31, 2022 | -309.00% |
| Sep 30, 2022 | -223.68% |
| Jun 30, 2022 | -185.09% |
| Mar 31, 2022 | -226.86% |
| Dec 31, 2021 | -179.56% |
| Jun 30, 2021 | -122.75% |